TrialBreast (Edinburgh, Scotland)2025

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy.

Charles E Geyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.